Related Experiment Video
Updated: Mar 17, 2026
10:39
Intranasal Administration of Recombinant Influenza Vaccines in Chimeric Mouse Models to Study Mucosal Immunity
Published on: June 25, 2015
13.3K
Fluzone® Intradermal Quadrivalent Influenza Vaccine
Corwin A Robertson1, Peter Tsang2, Victoria A Landolfi3
1a Scientific and Medical Affairs Department , Sanofi Pasteur Inc ., Discovery Drive, Swiftwater , PA , USA.
Expert Review of Vaccines
|July 27, 2016
Summary
Fluzone Intradermal Quadrivalent vaccine offers enhanced influenza protection by including two B lineage strains. Its innovative microinjection system aims to improve vaccine administration for healthcare providers.
Area of Science:
- Vaccinology
- Immunology
- Public Health
Background:
- Intradermal influenza vaccination was introduced for adults aged 18-64 years in the 2011-2012 season with a trivalent formulation.
- The trivalent Fluzone Intradermal vaccine contained 9 µg hemagglutinin per strain for A/H1N1, A/H3N2, and one B lineage virus.
Purpose of the Study:
- To review the history and mechanism of intradermal vaccination.
- To discuss clinical trial data on the immunogenicity and safety of Fluzone Intradermal Quadrivalent vaccine.
- To describe the microinjection system used for Fluzone Intradermal Quadrivalent delivery.
Main Methods:
- Literature review of intradermal vaccination history and mechanisms.
- Analysis of clinical trial results for Fluzone Intradermal Quadrivalent vaccine.
- Description of the vaccine's microinjection delivery system.
Main Results:
- Fluzone Intradermal Quadrivalent vaccine was introduced for the 2015-2016 season, replacing the trivalent version.
- The quadrivalent vaccine includes 9 µg hemagglutinin per strain for two A strains and both B lineage strains (Victoria and Yamagata).
- Clinical trials support the immunogenicity and safety of the quadrivalent formulation.
Conclusions:
- Fluzone Intradermal Quadrivalent vaccine enhances influenza immunization by incorporating both B lineage strains.
- The vaccine's microinjection system addresses logistical challenges in immunization delivery.
- This formulation may increase confidence in influenza vaccination efficacy.
